Psoriasis Clinical Trials

Showing 781-800 of 888 trials

COMPLETEDPhase 1/2

Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test

NCT02111499

Clinical investigation of anti-psoriatic efficacy and atrophy

Psoriasis

Almirall, S.A.18 participantsStarted Mar 2014

Schenefeld, Schleswig-Holstein, Germany

COMPLETEDPhase 4

Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris

NCT02004574

The combination of calcipotriol and betamethasone dipropionate used in an ointment formulation (Daivobet® ointment) has shown to have an excellent efficacy and safety in the short-term and long-term management of psoriasis vulgaris. A newly developed gel formulation (Xamiol® gel) of calcipotriol and betamethasone dipropionate has recently been approved and marketed in Korea as a topical treatment of moderate to severe scalp psoriasis and non-scalp psoriasis vulgaris. Xamiol® gel, the investigational product (IP) used in this study, prevents keratinization by normalizing the reproduction cycle of skin cells. It also relieves itching associated with psoriasis. Xamiol® gel was initially approved for treatment of moderate to severe scalp psoriasis and its label was extended to non-scalp psoriasis vulgaris in October 2012. Since patient compliance is one of the important factors in achieving effective outcomes in the treatment of psoriasis, the once daily dosing of Xamiol® gel is expected to enhance compliance and treatment outcomes as well as to provide a safe and effective therapeutic option.

Psoriasis Vulgaris

Jooheung Lee201 participantsStarted Oct 2013

Gangnam-gu, Seoul, South Korea

Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test

Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris

Related Searches

Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab

Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab

ChangE From Any Systemic psoriasiS therapY to Raptiva

Impact of Literacy Level on Patient Education and Health Among People With Arthritis

The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients

Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment

Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)

Conditioning, the Placebo Effect, and Psoriasis

Surveillance of Humira Injection in Korean Patients

Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients

The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis

Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis

Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis

Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis

Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis

Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

Functional Limitations Due To The Foot Involvement In Spondyloarthritis